David S. Hong, Ignacio Garrido-Laguna, Suhendan Ekmekcioglu, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, Siqing Fu, Stacy L. Moulder, Sarina Piha-Paul, Apostolia M. Tsimberidou, YueJin Wen, Kirk S. Culotta, Kenna Anderes, Darren W. Davis, Wen Liu, Goldy C. George, Luis H. Camacho, Susan Percy Ivy and Razelle Kurzrock Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors Cancer 120
Version of Record online: 17 APR 2014 | DOI: 10.1002/cncr.28701
Targeting angiogenesis and disrupting the cross-talk between stroma and cancer cells is a promising strategy for cancer treatment. Vascular endothelial growth factor is critical in orchestrating neoangiogenesis. The current study was conducted to evaluate the safety and biological activity of the dual inhibition of the vascular endothelial growth factor pathway with combined bevacizumab and cediranib.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field